Bio-K+CL1285(R) is currently used in 36 Canadian hospitals and health centres, and is sold in the health specialized sections of grocery stores, pharmacies and health stores across Canada and US. About Bio-K+ International Inc. Founded in 1994, Bio-K+ International Inc. is a family-owned Canadian biotech company with its head offices located in Laval’s scientific and high-tech park. With more than 65 employees, Bio-K+ International Inc. is dedicated to the manufacture, distribution and sale of Bio-K+CL1285(R) products. For more information, please visit the web site http://www.biokplus.com . Canadian Journal of Gastroenterology: http://www.pulsus.com/journals/toc.jsp?sCurrPg=journal&jnlKy =2&fold=Current%20Issue—————————— (1) Effect of fermented milk combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: A randomized, double-blind, placebo-controlled trial, CANJ Gastroenterology, Vol 21, No 11, November 2007, 732:736. (2) Product and placebo were provided by Bio-K+ International Inc, which also provided a research grant to cover the pharmacy administration fees. (3) Canadian Bacterial Surveillance Network, February 2006, and CMA Foundation, 2006. (4) McFarland LV.
REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients
The REACT (Randomized Evaluation of an Algorithm for Crohn’s Treatment) study, led by Robarts Clinical Trials at Western University (London, Canada) provides valuable new insights for community gastroenterologists which should benefit patients. The results of the study will be presented at the European Crohn’s and Colitis Organisation (ECCO) annual congress taking place in Copenhagen, Denmark on February 20-22, 2014. Crohn’s disease is a chronic, potentially debilitating, condition of the gastrointestinal tract which can cause abdominal pain, diarrhea, vomiting, and weight loss among other symptoms. Well over five million people globally are affected by Crohn’s disease and ulcerative colitis. Dr. Brian Feagan, CEO and Senior Scientific Director of Robarts Clinical Trials and a professor in the Division of Gastroenterology at Western’s Schulich School of Medicine & Dentistry, says the medical management of Crohn’s disease has undergone important changes over the past two decades with the introduction of TNF antagonists such as adalimumab and infliximab. The current treatment approach features sequential and incremental treatment intensification based on symptoms. In contrast, an accelerated step-care approach involves the early introduction of combined immunosuppression in high risk patients, which has been shown to induce and maintain remission, reduce the use of corticosteroids, and heal intestinal ulceration in those who fail conventional treatment. Subsequent research, performed in both Crohn’s disease and rheumatoid arthritis, indicated that TNF antagonists work best when: 1) used in combination with antimetabolites (e.g., azathioprine, methotrexate) and 2) introduced early in the course of the disease. Controlled studies such as CHARM (Crohn’s Trial of the Fully Human Antibody Adalimumab for Remission Maintenance) have also demonstrated that TNF antagonist-based regimens can reduce the rate of surgery and hospitalization in comparison to conventional therapy. “However, adoption of these key concepts by community gastroenterologists has been relatively slow,” says Dr. Feagan. “This is primarily because many believe that the safety and efficacy of these agents may not be generalizable to their individual practice, since they were tested in academic centers. The REACT study was designed to address these concerns.” In this cluster-randomized trial, 39 community gastroenterology practices in Canada or Belgium were randomly assigned to a conventional management approach or to an accelerated step-care algorithm that featured early use of combined adalimumab/antimetabolite therapy. Within practices, up to 60 consecutive patients were entered and evaluated for 24 months to determine whether the implementation of an accelerated step-care approach would improve the management of Crohn’s disease in comparison to conventional management methods. Final results from the REACT clinical trial showed the proportion of patients in remission at 12 months was marginally greater in the group assigned to accelerated step-care.
Atlanta-Based EndoChoice Approved To Market Full-Spectrum Endoscopy System In Canada
The Fuse endoscopy system is comprised of colonoscopes and gastroscopes with multiple imagers enabling doctors to see more of the GI tract for diagnosis and treatment. Standard, forward-viewing endoscopy systems have a single imager so clinicians are switching to the Fuse system in an effort to improve the quality of their procedures. The Health Canada license means its Fuse system will be the first endoscopy equipment available with expanded viewing capabilities to reach Canadian patients, the company said. Endoscopes are thin flexible tubes with imaging capabilities that doctors use to view the upper and lower GI tracts of their patients. The news from Health Canada enables EndoChoice to begin delivering Fuse endoscopy systems to their gastroenterology specialist customers throughout Canada . “We intend to gain market clearance in several more countries in the near future,” said Mark Gilreath, Founder and CEO at EndoChoice. “While 2013 has been an exciting year for our company, the introduction of Fuse into Canada and other markets will enable us to make 2014 even more dynamic as we bring this game-changing technology to more clinicians.” EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio.